Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 16/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.60 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4417313 | 1.00 | ITGA4 (0.62) | ITGA4ITGB3ITGA2BPTPN1ITGB1 | |
| SCHEMBL1309887 | 1.00 | ITGA4 (0.62) | ITGA4ITGB3ITGA2BPTPN1ITGB1 | |
| SCHEMBL10883351 | 0.91 | ITGA4 (0.52) | ITGA4ITGB3ITGA2BPTPN1ITGB1 | |
| SCHEMBL6129624 | 0.89 | PTPN1 (0.61) | ITGA4ITGB3ITGA2BPTPN1ITGB1 | |
| SCHEMBL6129676 | 0.89 | PTPN1 (0.61) | ITGA4ITGB3ITGA2BPTPN1ITGB1 | |
| SCHEMBL7340367 | 0.89 | ITGA4 (0.57) | ITGA4ITGB3ITGA2BPTPN1ITGB1 | |
| SCHEMBL7340357 | 0.89 | ITGA4 (0.57) | ITGA4ITGB3ITGA2BPTPN1ITGB1 | |
| SCHEMBL8925517 | 0.88 | PTPN1 (0.66) | ITGA4ITGB3ITGA2BPTPN1 | |
| SCHEMBL193474 | 0.85 | PTPN1 (0.73) | ITGB3ITGA2BPTPN1 | |
| SCHEMBL193473 | 0.85 | PTPN1 (0.73) | ITGB3ITGA2BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115169-B2 | Method of treating tumors | LYTIX BIOPHARMA AS (NO) | 2015-08-25 | — | — | US | disclosed |
| US-9109048-B2 | Inhibition of tumor growth | LYTIX BIOPHARMA AS (NO) | 2015-08-18 | — | — | US | disclosed |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | LYTIX BIOPHARMA AS (NO) | 2014-02-06 | — | — | US | disclosed |
| US-8283315-B2 | Inhibition of tumour growth | LYTIX BIOPHARMA AS (NO) | 2012-10-09 | — | — | US | disclosed |
| US-20120108520-A1 | Antimicrobial Compounds and Formulations | LYTIX BIOPHARMA AS (NO) | 2012-05-03 | — | — | US | disclosed |
| US-8143211-B2 | Bioactive peptides | LYTIX BIOPHARMA AS (NO) | 2012-03-27 | — | — | US | disclosed |
| US-8048852-B2 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2011-11-01 | — | — | US | disclosed |
| EP-1263471-B1 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | LYTIX BIOPHARMA AS (NO) | 2011-10-12 | — | — | EP | disclosed |
| EP-2338522-A1 | Antitumoural therapies | Lytix Biopharma AS (NO) | 2011-06-29 | — | — | EP | disclosed |
| EP-1109831-B1 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | LYTIX BIOPHARMA AS (NO) | 2011-01-12 | — | — | EP | disclosed |
| US-7232803-B2 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2007-06-19 | — | — | US | disclosed |
| US-6890902-B2 | Cytotoxic modified lactoferrin peptides | ALPHARMA AS (NO) | 2005-05-10 | — | — | US | disclosed |
| US-20030195144-A1 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2003-10-16 | — | — | US | disclosed |
| US-20030148936-A1 | Bioactive peptides | ALPHARMA AS. | 2003-08-07 | — | — | US | disclosed |
| US-20030022821-A1 | Bioactive peptides | ALPHARMA AS | 2003-01-30 | — | — | US | disclosed |
| EP-1263471-A2 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | ALPHARMA AS (NO) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001066147-A2 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | ALPHARMA AS (NO) | 2001-09-13 | — | — | WO | disclosed |
| EP-1109831-A2 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012541-A2 | CYTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
| US-4534897-A | Piperazinone, piperazine, 1,4-diazepin-2-one and 1,4-diazepine intermediate compounds | THE UPJOHN COMPANY (US) | 1985-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108520-A1 | Antimicrobial Compounds and Formulations | VIP, NONO, CLPTM1 | ITGA4 2575/4885ITGB3 1781/4885ITGA2B 3032/4885 |
| US-20030148936-A1 | Bioactive peptides | VIP, NGLY1, HM13 | ITGA4 4539/4885ITGB3 3804/4885ITGA2B 4354/4885 |
| US-20030195144-A1 | Antimicrobial compounds and formulations | LPO, CLPTM1, VIP | ITGA4 3284/4885ITGB3 2378/4885ITGA2B 3075/4885 |
| US-20030022821-A1 | Bioactive peptides | VIP, LITAF, LNPEP | ITGA4 3238/4885ITGB3 2610/4885ITGA2B 3218/4885 |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | STING1, VIP, MIF | ITGA4 3403/4885ITGB3 3720/4885ITGA2B 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.